HutchMED (China) LIMITED revenue by segment HCM

Annual Quarterly

HutchMED (China) LIMITED splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Oncology Or Immunology at $285.5 million, 52% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Goods Distribution at $263.0 million, 48% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	549	630	838	426	356	228	205	214	241	216
Operating segments
Oncology Or Immunology	286 -21.4% share 52.1%	363 -31.3% share 57.7%	529 +222.6% share 63.1%	164 +37.0% share 38.4%	120 +295.9% share 33.6%	30 +12.8% share 13.3%	27 share 13.1%	—	—	—
Other Ventures	263 -1.4% share 47.9%	267 -13.8% share 42.3%	309 +17.8% share 36.9%	263 +11.0% share 61.6%	237 +19.6% share 66.4%	198 +11.0% share 86.7%	178 share 86.9%	—	—	—
Sales mix
Goods Distribution	263 share 47.9%	—	309 +17.8% share 36.9%	263 +11.0% share 61.6%	237 +19.6% share 66.4%	198 +12.7% share 86.7%	176 +8.9% share 85.7%	161 -20.7% share 75.3%	203 share 84.3%	—
Marketed Products	101 -21.4% share 18.3%	128 +54.1% share 20.3%	83 share 9.9%	—	—	11 share 5.0%	—	—	—	—
Other Collaboration Royalties Revenue	68 -3.7% share 12.5%	71 +118.8% share 11.3%	32 +23.4% share 3.9%	26 +74.7% share 6.2%	15 share 4.2%	—	—	—	—	—
Commercialization Services	45 share 8.3%	—	49 share 5.8%	—	27 +634.5% share 7.7%	4 share 1.6%	—	—	—	—
License And Collaborations Manufacturing Supply	31 +200.1% share 5.7%	10 +120.3% share 1.6%	5 share 0.6%	—	—	—	—	—	—	—
Collaboration Research And Development	28 -51.9% share 5.1%	58 share 9.2%	—	24 +25.0% share 5.6%	19 share 5.3%	—	—	—	—	—
Other Collaboration Licensing Revenue	12 -71.9% share 2.2%	43 -84.6% share 6.8%	279 +1764.8% share 33.3%	15 -36.8% share 3.5%	24 share 6.6%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: HCM (Nasdaq), HMDCF (OTC)
Incorporated in: Cayman Islands
Headquarters: Hong Kong
SEC filer status: Large accelerated filer
SEC CIK: 1648257
Former names: Hutchison China MediTech Ltd (until Apr 29, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.